(31 March, 2025) BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today, that the company was granted important patent claims in China for its BV100 technology.

（25 February, 2025) Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks. 

（11 February, 2025) BioVersys AG (SIX: BIOV) announced today that its BV500 NTM program has reached its second milestone, “identification of up to 5 Optimized Lead compounds”, under the CF AMR Syndicate Collaborative Discovery Programme (CDP) agreement. Supported by LifeArc funding, BioVersys is developing novel small molecules targeting difficult to treat non-tuberculous mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

(7 February, 2025) Today, BioVersys (Ticker “BIOV”), a leading Swiss biotech company specializing in novel antibacterial products for serious life-threatening infections, listed its shares at SIX Swiss Exchange. At an opening price of CHF 36.50 per share, the resulting market capitalization of BioVersys was around CHF 216 million.

(29 Janruary, 2025) Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company’s ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share.

(28 Janruary, 2025) New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastases. 

(21 January, 2025) BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today that it plans to conduct an initial public offering (“IPO”) on the SIX Swiss Exchange in the first quarter of 2025.

(25 October, 2024) Corneat Vision, a project invested by GIBF, recently featured on a France TV show with the story the first French patient who received a new and entirely artificial cornea- the Corneat KPro. 

(22 October, 2024) RespiriNTM Programme allows BioVersys’ NTM project to access up to €2 million of non-dilutive funding.

(16 October, 2024) BioVersys's BV100 Phase 2 preliminary results suggest BV100 is generally safe and well tolerated and showed strong initial signs of efficacy in VABP patients.

(1 October, 2024) Latest preclinical studies reveal significant improvements in stability, efficacy, and KRAS targeting range for next-generation siRNA candidate SIL-204.

（24 September, 2024）New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer

(11 September, 2024) GIBF announced today that it has successfully participated in the Series C+ round of financing of the Swiss-based company, BioVersys AG, with a total investment amount of 6 million US dollars (approx. 42.5 million RMB). 

Nectin Therapeutics, Ltd., the parent company of Guangzhou Nectin Pharmaceutical Co., Ltd., a project invested by GIBF2 recently announced a global exclusive license agreement with Immunome Inc. for a monoclonal antibody molecule. 

Recently, the American medical device giant Edwards Lifesciences announced the completion of the acquisition of Innovalve Bio Medical (hereinafter referred to as Innovalve), a spin-off from the Sheba Medical Center in Israel, for $300 million in cash. The acquisition plan is expected to be completed by the end of 2024, at which time Innovalve will be integrated into Edwards Lifesciences' Transcatheter Mitral and Tricuspid Valve Therapies (TMVT) 'product group, a news that has attracted widespread attention in the biomedical field. 

(6 May, 2024) Guangzhou-Israel Biotechnology Fund (GIBF) announced today that it has invested $10 million in Nectin Therapeutics Ltd, proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates.

(18 March, 2024) Nectin Therapeutics Ltd. (" Nectin "), the parent company of Guangzhou Nectin Pharma Ltd. has been selected as one of the 42 recipients of EIC funding in the 2023 EIC Accelerator from a competitive field of 1,083 proposals and 242 companies that were reviewed.

(25 Dec, 2023) Israeli Foreign Affairs Minister Mr. Eli Cohen awarded certificates of appreciation to businessmen and organizations for their contribution to Israel's foreign relations and strengthening its global position.

(16 Nov, 2023) Visionix USA is proud to share they recently entered a strategic alliance with 20/20NOW to help bring cost effective, in-office, quality synchronous tele-optometry comprehensive eye exams and ocular telemedicine closer to more patients throughout the United States.

(30 Oct, 2023) Results from a multinational Phase 2 clinical study (Protact Trial) of siRNA directed against the oncogenic KRAS G12D and G12V mutations  in an extended release formulation (Loder™) was presented at the 2023 European Society for Medical Oncology (ESMO) annual congress (Abstract 1626P). 

(8 Jun, 2023) CorNeat Vision's EverPatch utilizes EverMatrix™, a novel material technology able to integrate with surrounding tissue

(18 Sep, 2022) Kamari Pharma announced the completion of an $8 million investment by the Chinese fund GIBF2.

(11 Sep, 2021) Guangzhou Sino-Israel Biotech Investment Fund (GIBF) recently completed a $ 4 million investment in the Israeli subsidiary of Kornit Vision, which was established in Guangzhou, China.

(31 May 2021) The Guangzhou Sino-Israel Bio-industry Investment Fund, headed by Israel’s former chief scientist, has already closed $200 million for its second fund to finance clinical trials.